Search

Your search keyword '"Enns, Justine"' showing total 14 results
Start Over Author "Enns, Justine"
14 results on '"Enns, Justine"'

7. Erratum to: Experience and Outcomes of Breastfed Infants of Women Living with HIV in the United States: Findings from a Single Center Breastfeeding Support Initiative

Author

Yusuf, Hasiya E, primary, Knott-Grasso, Mary Ann, additional, Anderson, Jean, additional, Livingston, Alison, additional, Rosenblum, Nadine, additional, Sturdivant, Heather, additional, Byrnes, Kristen C, additional, Powell, Anna, additional, Sheffield, Jeanne S, additional, Enns, Justine, additional, Persaud, Deborah, additional, Golden, W Christopher, additional, and Agwu, Allison L, additional

Published
2022
Full Text
View/download PDF

8. Experience and Outcomes of Breastfed Infants of Women Living With HIV in the United States: Findings From a Single-Center Breastfeeding Support Initiative

Author

Yusuf, Hasiya E, primary, Knott-Grasso, Mary Ann, additional, Anderson, Jean, additional, Livingston, Alison, additional, Rosenblum, Nadine, additional, Sturdivant, Heather, additional, Byrnes, Kristen C, additional, Powell, Anna, additional, Sheffield, Jeanne S, additional, Enns, Justine, additional, Persaud, Deborah, additional, Golden, William Christopher, additional, and Agwu, Allison L, additional

Published
2021
Full Text
View/download PDF

10. Experience and Outcomes of Breastfed Infants of Women Living With HIV in the United States: Findings From a Single-Center Breastfeeding Support Initiative.

Author

Yusuf, Hasiya E, Knott-Grasso, Mary Ann, Anderson, Jean, Livingston, Alison, Rosenblum, Nadine, Sturdivant, Heather, Byrnes, Kristen C, Powell, Anna, Sheffield, Jeanne S, Enns, Justine, Persaud, Deborah, Golden, William Christopher, and Agwu, Allison L

Subjects
EVALUATION of medical care, HIV-positive persons, BREASTFEEDING, INFECTIOUS disease transmission
Abstract

We assessed breastfeeding outcomes for a cohort of infants born to women living with HIV (WLHIV) at an urban health care center in the United States. Ten infants were exclusively breastfed for a mean duration of 4.4 (1.0-8.6) months. All had negative HIV RNA PCRs at a median age of 16 months. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

13. Cannabidiol modulates serotonergic transmission and reverses both allodynia and anxiety-like behavior in a model of neuropathic pain

Author

Ryan J. McLaughlin, Gabriella Gobbi, Sabatino Maione, Martha Lopez-Canul, Matthew Kaba Aboud, Luca Posa, Stefano Comai, Justine P Enns, Danilo De Gregorio, Rafael Ochoa-Sanchez, De Gregorio, Danilo, Mclaughlin, Ryan J., Posa, Luca, Ochoa-Sanchez, Rafael, Enns, Justine, Lopez-Canul, Martha, Aboud, Matthew, Maione, Sabatino, Comai, Stefano, and Gobbi, Gabriella

Subjects
Male, Anxiety, Cannabidiol, Dorsal raphe, Electrophysiology, Pain, Pyridines, Action Potentials, Pharmacology, Piperazines, chemistry.chemical_compound, 0302 clinical medicine, Piperidines, 030202 anesthesiology, Ganglia, Spinal, Allodynia, Neurology, Hyperalgesia, Neuropathic pain, Serotonin Antagonists, medicine.symptom, Capsazepine, medicine.drug, Elevated plus maze, Serotonin, medicine.drug_class, TRPV1, Anxiolytic, 03 medical and health sciences, medicine, Animals, Rats, Wistar, Maze Learning, Swimming, business.industry, Antagonist, Feeding Behavior, Rats, Disease Models, Animal, Lysergic Acid Diethylamide, Anesthesiology and Pain Medicine, chemistry, Exploratory Behavior, Neuralgia, Pyrazoles, Neurology (clinical), Capsaicin, business, 030217 neurology & neurosurgery
Abstract

Clinical studies indicate that cannabidiol (CBD), the primary nonaddictive component of cannabis that interacts with the serotonin (5-HT)1A receptor, may possess analgesic and anxiolytic effects. However, its effects on 5-HT neuronal activity, as well as its impact on models of neuropathic pain are unknown. First, using in vivo single-unit extracellular recordings in rats, we demonstrated that acute intravenous (i.v.) increasing doses of CBD (0.1-1.0 mg/kg) decreased the firing rate of 5-HT neurons in the dorsal raphe nucleus, which was prevented by administration of the 5-HT1A antagonist WAY 100635 (0.3 mg/kg, i.v.) and the TRPV1 antagonist capsazepine (1 mg/kg, i.v.) but not by the CB1 receptor antagonist AM 251 (1 mg/kg, i.v.). Repeated treatment with CBD (5 mg/kg/day, subcutaneously [s.c.], for 7 days) increased 5-HT firing through desensitization of 5-HT1A receptors. Rats subjected to the spared nerve injury model for 24 days showed decreased 5-HT firing activity, mechanical allodynia, and increased anxiety-like behavior in the elevated plus maze test, open-field test, and novelty-suppressed feeding test. Seven days of treatment with CBD reduced mechanical allodynia, decreased anxiety-like behavior, and normalized 5-HT activity. Antiallodynic effects of CBD were fully prevented by capsazepine (10 mg/kg/day, s.c., for 7 days) and partially prevented by WAY 100635 (2 mg/kg/day, s.c., for 7 days), whereas the anxiolytic effect was blocked only by WAY. Overall, repeated treatment with low-dose CBD induces analgesia predominantly through TRPV1 activation, reduces anxiety through 5-HT1A receptor activation, and rescues impaired 5-HT neurotransmission under neuropathic pain conditions.

Published
2019

14. d-Lysergic acid diethylamide, psilocybin, and other classic hallucinogens: Mechanism of action and potential therapeutic applications in mood disorders.

Author

De Gregorio D, Enns JP, Nuñez NA, Posa L, and Gobbi G

Subjects
Animals, Hallucinogens pharmacology, Humans, Lysergic Acid Diethylamide pharmacology, Psilocybin pharmacology, Hallucinogens therapeutic use, Lysergic Acid Diethylamide therapeutic use, Mood Disorders drug therapy, Psilocybin therapeutic use
Abstract

Depression and anxiety are psychiatric diagnoses commonly associated with low quality of life and low percentage of responsiveness by patients treated with currently available drugs. Thus, research into alternative compounds to treat these disorders is essential to guarantee a patient's remission. The last decade has witnessed a revamped interest for the application of psychedelic medicine for the treatment of mental disorders due to anecdotal reports and clinical studies which show that low doses of d-lysergic acid diethylamide (LSD) and psilocybin may have antidepressant effects. LSD and psilocybin have demonstrated mood-modulating properties likely due to their capacity to modulate serotonergic (5-HT), dopaminergic (DA) and glutamatergic systems. LSD, belonging to the category of "classic halluginogens," interacts with the 5-HT system through 5HT 1A , and 5HT 2A receptors, with the DA system through D 2 receptors, and indirectly also the glutamatergic neurotransmission thought the recruitment of N-methyl-d-aspartate (NMDA) receptors. Randomized clinical studies have confirmed its antidepressant and anxiolytic effects in humans. Thus, in this chapter, we will review the pharmacology of psychedelic drugs, report the most striking clinical evidence which substantiate the therapeutic potentials of these fascinating compounds in mood disorders, and look into the horizon of where psychedelic medicine is heading., (© 2018 Elsevier B.V. All rights reserved.)

Published
2018
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results